On September 21, AKESO rose 3.65% in regular trading, trading at HK$93.8/share, with turnover of HK$161 million. The gain comes amid continued positive sentiment following a wave of brokerage upgrades and landmark clinical data.

Most recently, CICC raised its target price for AKESO by 8.3% to HK$130, maintaining an Outperform rating, citing the impressive overall survival (OS) data from the HARMONi-2 trial and increased confidence in the global Phase 3 HARMONi-7 trial. Earlier, Jefferies maintained a Buy rating with a HK$226 target, while Citi reiterated Buy at HK$171, and JPMorgan maintained Overweight, all highlighting the robust OS results from ivonescimab versus pembrolizumab.

The HARMONi-2 study, presented at the 2026 World Conference on Lung Cancer, showed ivonescimab achieved a median OS of 30.8 months compared to 22.6 months for pembrolizumab (HR 0.73, p=0.009), marking a statistically significant survival advantage in first-line PD-L1-positive NSCLC treatment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)